Will 'OPEC Plus' Agreement to Cut Production End?

OPEC Plus meeting late June will significantly determine future of oil prices. Reuters
OPEC Plus meeting late June will significantly determine future of oil prices. Reuters
TT

Will 'OPEC Plus' Agreement to Cut Production End?

OPEC Plus meeting late June will significantly determine future of oil prices. Reuters
OPEC Plus meeting late June will significantly determine future of oil prices. Reuters

Economic policymakers in the Organization of the Petroleum Exporting Countries (OPEC) are most concerned about the drop in oil prices this year, which is likely to decline if the OPEC and non-OPEC members (known as OPEC plus) decide to raise their production two weeks from now.

Notably, OPEC plus refers to OPEC’s cooperation with non-OPEC oil producers to affect production cuts.

However, will prices fall? And will this agreement end?

It seems that the cut-off deal is on its way to end this month although OPEC members have a strong desire to extend it until the end of the year.

There is plenty of evidence suggesting that the agreement may end, yet this will not be certain until the end of the meeting on June 23.

The first evidence is that Russians are pushing hard to raise their production and stop the agreement as it is clear from the statements of heads of Russian oil companies, such as Gazprom Neft or Rosneft.

They stated in the last two weeks that the production of Russian companies should increase after the oil market showed a balance and a significant decline in stocks.

Most major Russian oil companies also support increased crude production as prices hit $80 per barrel last month. Oil is currently traded at more than $76 per barrel.

OPEC and non-OPEC ministers will meet in Vienna on June 22-23 to discuss the future of the deal, which is valid until the end of the year.

Although Russian politicians have not publicly stated this, Russian President Vladimir Putin told senior world news editors in St. Petersburg late last month that Russia's agreement with OPEC was not to last forever, and that Russia sees the oil market now balanced. Putin also said a price of $60 “suits” his country.

Russia and OPEC leader Saudi Arabia have signaled there could be a need to gradually boost production to prevent any supply shortages.

Russian oil output was stagnant at 10.97 million bpd for the third month in a row in May.

Meanwhile, Russian news agency Interfax reported on Saturday that Russia's oil production had risen to 11.1 million bpd in early June, above its target production of under 11 million bpd as part of the deal.

The country agreed to cut its production by 300,000 bpd from 11.24 million bpd as part of a global pact. The Russian Energy Ministry did not immediately respond to a request for comment.

Interfax said Russian oil production stood on average at 1.51 million tons per day in the first week of the month and never got below 1.51 million tons.



UAE’s Mubadala Acquires Majority Stakes in Global Medical Supply Chain, Al Ittihad Drug

The acquisition enhances Mubadala's footprint in the healthcare logistics and pharmaceutical distribution sectors. WAM
The acquisition enhances Mubadala's footprint in the healthcare logistics and pharmaceutical distribution sectors. WAM
TT

UAE’s Mubadala Acquires Majority Stakes in Global Medical Supply Chain, Al Ittihad Drug

The acquisition enhances Mubadala's footprint in the healthcare logistics and pharmaceutical distribution sectors. WAM
The acquisition enhances Mubadala's footprint in the healthcare logistics and pharmaceutical distribution sectors. WAM

Mubadala Investment Company has acquired an 80% stake in Global Medical Supply Chain (GMSC) and Al Ittihad Drug Store (IDS) from GlobalOne Healthcare Holding (GHH), with GHH retaining a 20% stake, Emirates News Agency (WAM) reported on Tuesday.

This strategic acquisition enhances Mubadala's footprint in the healthcare logistics and pharmaceutical distribution sectors, aligning with the UAE's vision to establish a robust life sciences infrastructure, WAM said.

Founded in 2015, GMSC provides comprehensive end-to-end supply chain services for medical products, including demand planning, procurement, logistics, inventory management, warehousing, and maintenance.

GMSC serves over 200 medical facilities, including hospitals and clinics across the UAE. With a dedicated team of medical supply chain specialists, GMSC sources a broad array of products from almost 400 suppliers, ensuring a reliable supply chain for all medical needs.

IDS, established in 1987, stands as one of the leading distributors of pharmaceutical and consumer healthcare products in the UAE. Distributing over 1,000 products from over 40 leading suppliers, IDS services every hospital, and all, or at least most pharmacies and supermarkets within the UAE. It boasts a vast portfolio that spans multiple therapeutic categories including anti-infectives, asthma, diabetes, and oncology.

"The expanding pharmaceutical market drives an increasing demand for specialized and efficient drug logistics solutions. By integrating GMSC and IDS into our portfolio, we are poised to create a vertically integrated life sciences sector in the UAE and enable its potential to encompass the entire value chain from logistics and distribution to specialized manufacturing,” said Executive Director of UAE Clusters at Mubadala's UAE Investments Platform Ismail Ali Abdulla.

As for Low Ping, Group CEO Yas Holding, she said that the transaction “continues Mubadala's strategic growth, following another significant acquisition by its new speciality pharmaceutical business, KELIX bio, which recently acquired a 100% stake in four pharma assets from GlobalOne Healthcare Holding's, the healthcare division of Yas Holding.”

“These concerted efforts underline Mubadala's commitment to strengthening the UAE's healthcare and pharmaceutical sectors as part of broader national ambitions for drug security and economic diversification."

GlobalOne Healthcare Holding LLC serves as the dedicated Healthcare Division of Yas Holding LLC, focusing on enhancing healthcare outcomes by investing in innovative solutions across various healthcare verticals.